See more : HMA Agro Industries Limited (HMAAGRO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Strongbridge Biopharma plc (SBBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Strongbridge Biopharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Strat Petroleum, Ltd. (SPRL) Income Statement Analysis – Financial Results
- National Electronics Holdings Limited (0213.HK) Income Statement Analysis – Financial Results
- WestKam Gold Corp. (WKGFF) Income Statement Analysis – Financial Results
- PS Business Parks, Inc. (PSB-PX) Income Statement Analysis – Financial Results
- Clarent Corporation (CLRN) Income Statement Analysis – Financial Results
Strongbridge Biopharma plc (SBBP)
About Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.73M | 21.71M | 18.03M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.21M | 3.82M | 3.99M | 1.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 28.52M | 17.89M | 14.04M | 5.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 92.80% | 82.40% | 77.89% | 78.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.80M | 30.90M | 25.44M | 17.27M | 20.02M | 20.14M | 5.84M | 2.53M |
| General & Administrative | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.87M | 45.81M | 63.34M | 36.29M | 14.88M | 22.72M | 4.59M | 0.00 |
| Other Expenses | 5.02M | 5.02M | 7.19M | 5.02M | 0.00 | 0.00 | 0.00 | -7.73M |
| Operating Expenses | 71.68M | 81.74M | 95.96M | 58.58M | 34.90M | 42.85M | 10.43M | -5.19M |
| Cost & Expenses | 73.90M | 85.56M | 99.95M | 60.07M | 34.90M | 42.85M | 10.43M | 5.19M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 25.00K | 0.00 | 0.00 |
| Interest Expense | 1.34M | 0.00 | 12.52M | 4.31M | 20.00K | 3.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.11M | 5.10M | 7.23M | 5.03M | 10.00K | 11.00K | 6.00K | 3.00K |
| EBITDA | -38.65M | -42.58M | 52.14M | -102.37M | -51.21M | -44.02M | -10.14M | -5.39M |
| EBITDA Ratio | -125.76% | -196.13% | 289.21% | -1,452.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.17M | -63.85M | -81.92M | -53.02M | -34.90M | -42.85M | -10.43M | -5.19M |
| Operating Income Ratio | -140.46% | -294.05% | -454.45% | -752.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.93M | 16.16M | 114.31M | -58.69M | -16.46M | -1.23M | 282.00K | -288.00K |
| Income Before Tax | -45.09M | -47.68M | 32.39M | -111.71M | -51.36M | -44.08M | -10.15M | -5.48M |
| Income Before Tax Ratio | -146.72% | -219.62% | 179.66% | -1,585.47% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -15.00K | 1.77M | 536.00K | 1.77M | -2.64M | -450.00K | -480.00K | -93.00K |
| Net Income | -45.08M | -49.45M | 31.85M | -113.48M | -48.60M | -43.58M | -9.67M | -5.30M |
| Net Income Ratio | -146.68% | -227.76% | 176.68% | -1,610.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.80 | -0.89 | 0.64 | -3.11 | -2.26 | -2.62 | -0.96 | -0.88 |
| EPS Diluted | -0.80 | -0.89 | 0.64 | -3.11 | -2.24 | -2.62 | -0.96 | -0.88 |
| Weighted Avg Shares Out | 56.11M | 55.38M | 49.72M | 36.54M | 21.55M | 16.61M | 10.11M | 6.02M |
| Weighted Avg Shares Out (Dil) | 56.11M | 55.38M | 49.72M | 36.54M | 21.66M | 16.61M | 10.11M | 6.02M |
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
Best Penny Stocks for Your Monday Watchlist? Check These 3 Out
SBBP Stock Price: Over 14% Increase Pre-Market Explanation
Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q1 2021 Results - Earnings Call Transcript
Strongbridge Biopharma (SBBP) Reports Q1 Loss, Tops Revenue Estimates
Recap: Strongbridge Biopharma Q1 Earnings
Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update
Strongbridge Biopharma Earnings Preview
Strongbridge: Approved Drugs, Near-Term Catalysts, Still Not Convinced
Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome in Frontiers in Endocrinology
Source: https://incomestatements.info
Category: Stock Reports